Alones Creative When I wrote about Verona Pharma plc (NASDAQ:VRNA) in February, the company was awaiting FDA approval of its drug ensifentrine for chronic obstructive pulmonary disease (COPD). I rated VRNA a hold then, noting there didn't seem to be much of a run up into approval underway, and there was room to fall if there was a delay in approval or outright rejection. June 26 came with news the FDA had indeed approved ensifentrine (Ohtuvayre) for the maintenance treatment of COPD, meaning a potential del ...